GLOBAL FOOD AND INGREDIT by Global Food and Ingredients Ltd. Bolsa (OTC: PEASF)

Últimas noticias sobre GLOBAL FOOD AND INGREDIT by Global Food and Ingredients Ltd. (OTC:PEASF) Bolsa

GLOBAL FOOD AND INGREDIT by Global Food and Ingredients Ltd.

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) Q1 expected to be below $0.02 vs $(0.14) Est..

News

Guidance

Under Armour Q1  expected to be below $0.02 vs $(0.14) Est

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) is looking for Q1 Adj EPS of $0.01-$0.03 vs $(0.08) analyst estimate. sees sales of $1.125 billion-$1.137 billion vs $1.17 billion analyst estimate.

Under Armour Sees Q1 Adj EPS $0.01-$0.03 vs $(0.08) Est; Sees Sales $1.125B-$1.137B vs $1.17B Est

Earnings

Earnings Beats

CYBR

CyberArk Software Q1 Adj. EPS $0.98 Beats $0.79 Estimate, Sales $317.60M Beat $305.23M Estimate

Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 128.57 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $36.84 million which beat the analyst consensus estimate of $32.76 million by 12.45 percent. This is a 2.07 percent decrease over sales of $37.62 million the same period last year.

BWEN

Broadwind Q1 EPS $(0.02) Beats $(0.04) Estimate, Sales $36.84M Beat $32.76M Estimate

Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) sees Q2 sales of $120.000 million-$123.000 million vs $119.01 million analyst estimate.

CAMT

Camtek Sees Q2 Sales $120.000M-$123.000M vs $119.01M Est

Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 73.68 percent increase over losses of $(0.38) per share from the same period last year.

ITRM

Iterum Therapeutics Q1 Adj. EPS $(0.10) Beats $(0.14) Estimate

Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.54) by 11.11 percent. This is a 92 percent decrease over losses of $(0.25) per share from the same period last year.

ABOS

Acumen Pharmaceuticals Q1 GAAP EPS $(0.48) Beats $(0.54) Estimate

Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.77 by 2.6 percent. This is a 23.44 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $118.60 million which missed the analyst consensus estimate of $119.28 million by 0.57 percent. This is a 22.14 percent increase over sales of $97.10 million the same period last year.

Earnings Misses

Camtek Q1 Adj. EPS $0.79 Beats $0.77 Estimate, Sales $118.60M Miss $119.28M Estimate

Needham analyst Quinn Bolton reiterates MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on MagnaChip Semiconductor, Maintains $6 Price Target

Full Year 2025 Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in millions, except per share amounts) (unaudited)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,710 - $1,734</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$463 - $478</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.21 - $2.51</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

PSFE

Paysafe Affirms FY2025 Adj EPS Guidance Of $2.21-$2.51 Vs $2.95 Est; Narrows FY2025 Sales Guidance Of $1.71B-$1.73B Vs $1.83B Est

Barclays analyst Julian Mitchell upgrades Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from Equal-Weight to Overweight and raises the price target from $69 to $90.

Upgrades

Barclays Upgrades Stanley Black & Decker to Overweight, Raises Price Target to $90

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.16 billion by 1.47 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.16B Estimate

Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.41 by 17.07 percent. This is a 40.35 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $401.00 million which missed the analyst consensus estimate of $404.56 million by 0.88 percent. This is a 4.01 percent decrease over sales of $417.74 million the same period last year.

Paysafe Q1 Adj. EPS $0.34 Misses $0.41 Estimate, Sales $401.00M Miss $404.56M Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Buy and maintains $40 price target.

DNTH

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.17 billion by 1.23 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.17B Estimate

Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) reported quarterly sales of $63.50 million which beat the analyst consensus estimate of $62.80 million by 1.11 percent. This is a 0.35 percent decrease over sales of $63.73 million the same period last year.

Endeavour Silver Q1 Sales $63.50M Beat $62.80M Estimate

Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and lowers the price target from $5 to $0.39.

Downgrades

AFMD

Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39

Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) reported $32.55 million in sales this quarter. This is a 46.30 percent increase over sales of $22.25 million the same period last year.

BETR

Better Home & Finance Q1 Sales $32.55M Up From $22.25M YoY, Adj. Net loss $46.18M Down From $42.83M YoY

Benchmark analyst Cody Acree maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and lowers the price target from $8 to $6.

INDI

Benchmark Maintains Buy on Indie Semiconductor, Lowers Price Target to $6

<ul>
<li>New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal cancer and non-small cell lung cancer cohorts of the Phase 1 KANDLELIT-001 study will be presented</li>
<li>Zilovertamab vedotin and sacituzumab tirumotecan data to highlight progress in Merck's pipeline of innovative antibody-drug conjugates</li>
<li>Follow-up data for KEYTRUDA&#xAE; (pembrolizumab) and WELIREG&#xAE; (belzutifan), as well as new and updated analyses for KEYTRUDA in earlier stages of cancer, add to the body of evidence supporting the role of these medicines</li>
</ul>

Comments

GLOBAL FOOD AND INGREDIT by Global Food and Ingredients Ltd.

Noticias

Últimas noticias sobre GLOBAL FOOD AND INGREDIT by Global Food and Ingredients Ltd. (OTC:PEASF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL